A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

Bio2RDF uri

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00040664

Bio2RDF identifier

NCT00040664

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00040664

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

This is a 48-week study ...... ed patients 2 - 18 years old.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Clinical Study Of An Investi ...... atric Subjects Ages 2-18 Years

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00040664 [clinicaltrials_resource:cc7fb5c57c00625c71964f1baab94aae]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:012460ce6fc7adf652370c864fbcc3fe]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:3b6fd80276240d6ac33c1b118b90277c]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:6b1db48cfa4185944500d2365b73439e]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:8759487388b6d119b4a4937063a8d2bc]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:98f7e0a6019463c8065a4c7d50872401]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:ac24b7adb99c987092a16942615181d6]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:ba4298518da27ff547ce9b9dc45f2a34]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:cc850eb44251e865cffd81a02679a969]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:d0b3cb0457e2258a9ec468d20ef76ebc]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:d168c518ccfcb5b5395f168e16913711]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:1e4c7fa59caeebda902e1e15f134ef4e]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:27c92b0165b7810a3c0c321964d2b392]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:72611b7aa02a8bdfc4ace6850d059520]

Number of Participants Who Discontinued Treatment Due to Adverse Events Baseline through end of study (at least Week 168) [clinicaltrials_resource:c4f74483bb8d8e76bebd5aae0a941fcf]

completion date [clinicaltrials_vocabulary:completion-date]

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

HIV Infection [clinicaltrials_resource:ae3faaf60bc156749e240922c496f046]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

detailed description [clinicaltrials_vocabulary:detailed-description]

A 48 Week, Phase II, Op ...... ect the change in sponsorship

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00040664 [clinicaltrials_resource:d6e017b0b5f01e8bca9eb1083440cbb0]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2002-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2009-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

ritonavir [clinicaltrials_resource:d60ed4e9764e78a06df19a53520ff0f7]

fosamprenavir [clinicaltrials_resource:f9262f2aaeac66a1745c867253dbf04d]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Fosamprenavir [clinicaltrials_resource:0e0ea01d62a6cb201b9a3130ec3ae5c5]

Ritonavir [clinicaltrials_resource:7dc4e4f837ab8fba1b64636daa50e0d3]

keyword [clinicaltrials_vocabulary:keyword]

AGENERASE

http://www.w3.org/2001/XMLSchema#string

HIV

http://www.w3.org/2001/XMLSchema#string

LEXIVA

http://www.w3.org/2001/XMLSchema#string

amprenavir

http://www.w3.org/2001/XMLSchema#string

fosamprenavir

http://www.w3.org/2001/XMLSchema#string

pediatrics

http://www.w3.org/2001/XMLSchema#string

protease inhibitors

http://www.w3.org/2001/XMLSchema#string

ritonavir

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2011-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

location [clinicaltrials_vocabulary:location]

GSK Investigational Site [clinicaltrials_resource:588f0eefe4495fd9f39a686d88ea391c]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00040664

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

See Detailed Description

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

APV 20003

http://www.w3.org/2001/XMLSchema#string

outcome [clinicaltrials_vocabulary:outcome]

Number of Participants Who Discontinued Treatment Due to Adverse Events [clinicaltrials_resource:NCT00040664/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

GSK Clinical Trials [clinicaltrials_resource:482ca15ed5613e7d70d0185ac9204ca5]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Canada: Health Canada [clinicaltrials_resource:50cb17af854a1e4590d4d933a86c89c4]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00040664 [clinicaltrials_resource:7be6f765546650b35d7f36f7abb1d08e]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00040664 [clinicaltrials_resource:56187b0428d981a19d92af4bbdf27251]

responsible party [clinicaltrials_vocabulary:responsible-party]

Study Director, GSK [clinicaltrials_resource:a453d54d68251d0a40603a6cb9bb7a6a]

source [clinicaltrials_vocabulary:source]

GlaxoSmithKline [clinicaltrials_resource:8075d9d563cbe75004e7b6c2c4360b29]

start date [clinicaltrials_vocabulary:start-date]

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00040664 study design [clinicaltrials_resource:749fcbcfb1b520d594bed558db7aa2d3]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00040664

verification date [clinicaltrials_vocabulary:verification-date]

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00040664

http://www.w3.org/2001/XMLSchema#string

title

A Clinical Study Of An Investi ...... atric Subjects Ages 2-18 Years

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3